Deletion mapping studies have found loss of PTEN in 26% of prostate tumors and functional analysis in murine models has shown that homozygous PTEN loss is sufficient to drive disease progression from early stages of prostate cancer formation to metastatic disease (38, 39). This evidence concerns the gene PTEN and prostate carcinoma.